This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran ...

While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the ...

One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for ...

A new study of nerve cells affected by Huntington’s disease (HD) reveals that the disease-causing gene slowly expands over ...

Notch Therapeutics is making “significant” layoffs to conserve its cash while the cell therapy biotech seeks out new partners ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...

Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...